Werewolf Therapeutics, INC

Werewolf Therapeutics reported Q2 2026 financial results, including $21.0 million in collaboration revenue from an asset sale, and provided an update on its strategic alternatives process.

Werewolf Therapeutics reported Q1 2026 results, announcing an asset purchase agreement with Jazz Pharmaceuticals for JZP898 and a repayment of debt, alongside reduced net losses.

Werewolf Therapeutics announced its fourth quarter and full year 2025 financial results and initiated a process to explore strategic alternatives to maximize stockholder value.

Werewolf Therapeutics, Inc. announced it will explore a full range of strategic alternatives to maximize stockholder value, engaging Piper Sandler & Co. as its exclusive financial advisor.

Werewolf Therapeutics announced a significant workforce reduction of 64%, the departure of its CFO and CMO, and ongoing efforts to secure capital and strategic partnerships.

Werewolf Therapeutics, Inc. received a deficiency letter from Nasdaq due to its common stock trading below the $1.00 minimum bid price requirement.

Werewolf Therapeutics, Inc. reported its second quarter 2026 financial results, highlighting a significant revenue stream from an asset sale to Jazz Pharmaceuticals, but also acknowledging substantial doubt about its ability to continue as a going concern.

Werewolf Therapeutics, Inc. filed its Form 10-Q for the quarter ended March 31, 2026, detailing a strategic review process, workforce reduction, and financial performance.

Werewolf Therapeutics, an early-stage biopharmaceutical company, reported substantial doubt about its ability to continue as a going concern, with significant cash burn and increased net losses.

Werewolf Therapeutics reported a wider net loss and increased cash burn in Q2 2025 as it advances its oncology pipeline and seeks future funding.

Werewolf Therapeutics reports a net loss for Q1 2025 but maintains a solid cash position expected to fund operations into Q4 2026.

Werewolf Therapeutics reports a net loss of $16.7 million for the third quarter of 2024, with ongoing clinical trials for WTX-124 and WTX-330.

Werewolf Therapeutics, Inc. announced a significant restructuring, including a 64% workforce reduction, and is exploring strategic alternatives to address substantial doubt about its ability to continue as a going concern.

Werewolf Therapeutics details its 2024 financial performance and outlines key developments in its clinical programs.

Werewolf Therapeutics reports a net loss of $37.4 million for 2023, alongside progress in clinical trials for its lead product candidates and a collaboration with Jazz Pharmaceuticals.

Director Luke Evnin reported transactions involving the sale of Werewolf Therapeutics, Inc. (HOWL) common stock, executed under a Rule 10b5-1 trading plan.

Luke Evnin, a Director at Werewolf Therapeutics, Inc., reported transactions involving the sale of common stock under a Rule 10b5-1 trading plan.

RA Capital Management has disclosed the sale of approximately 448,850 shares of Werewolf Therapeutics (HOWL) across three trading days in June 2026.

RA Capital Management has disclosed the sale of 678,226 shares of Werewolf Therapeutics (HOWL) across three days in June 2026.

Director Luke Evnin of Werewolf Therapeutics, Inc. reported the sale of 76,928 shares of common stock via a Rule 10b5-1 trading plan.

Director Luke Evnin of Werewolf Therapeutics, Inc. reported the sale of 105,565 shares of common stock via a Rule 10b5-1 trading plan.

Werewolf Therapeutics, Inc. announces its 2025 Annual Meeting of Shareholders to be held on June 12, 2025, featuring proposals including the election of directors and ratification of the company's accounting firm.

Werewolf Therapeutics announces its 2025 annual meeting of stockholders to be held virtually on June 12, 2025, to elect directors and ratify the appointment of Ernst & Young LLP as its independent auditor.

Werewolf Therapeutics, Inc. has filed a definitive proxy statement with the SEC.

Werewolf Therapeutics announces its 2024 annual meeting of stockholders to be held virtually on May 24, 2024, focusing on director elections and auditor ratification.

RA Capital Management and affiliated entities have filed an amendment to their Schedule 13D, reporting a decrease in their beneficial ownership of Werewolf Therapeutics, Inc. common stock.

RA Capital Management has disclosed a series of open market sales reducing its beneficial ownership in Werewolf Therapeutics, Inc. to 6.0%.

RA Capital Management has disclosed a reduction in its beneficial ownership of Werewolf Therapeutics common stock through a series of open market sales.

RA Capital Management reports a reduction in its beneficial ownership of Werewolf Therapeutics common stock following recent open market sales.

A group of investment entities affiliated with MPM Capital reported the sale of Werewolf Therapeutics common stock in the open market between May 6 and May 12, 2026.

MPM BioVentures and affiliated entities have disclosed the sale of shares in Werewolf Therapeutics, Inc. via an amended Schedule 13D filing.

Longwood Fund III GP, LLC and Longwood Fund III, L.P. have updated their beneficial ownership in Werewolf Therapeutics, Inc. to 3.5% as of December 31, 2025.

PFM Health Sciences and its affiliates have filed an amendment to their Schedule 13G, reporting a 0.9% beneficial ownership stake in Werewolf Therapeutics, Inc.

PFM Health Sciences, LP and its affiliates have filed an amended Schedule 13G, revealing a continued beneficial ownership of 6.5% in Werewolf Therapeutics, Inc. as of December 31, 2024.